Author expects Eli Lilly's Retatrutide to dominate competing drugs upon approval.
LLY — LONG The author argues Eli Lilly's investigational drug Retatrutide will be superior to competing therapies once approved. Approval serves as the concrete catalyst for a bullish position in Eli Lilly stock.
The new Lily drug (Retatrutide) is going to kill all the other ones off once it gets approved.
This Reddit post, published January 05, 2026, features u/CaptainChris1990 discussing LLY. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/CaptainChris1990 · Tickers: LLY